Evaluation and Treatment of Co-Factors in HIV disease progression

HIV Disease :Management of Co-Factors in disease progression

Co-factors that enhance progression/HIV replication	Co-factors that inhibit progression/HIV replication
Co-Infections HHV-1/Herpes Simplex Virus-1 HHV-2/Herpes Simplex Virus-2 HHV-3/CMV HHV-5/Varicella Zoster HHV-7 Hepatitis C Mycobacteria HHV-8/Kaposis Sarcoma Virus HHV-6a and b HHV-4a and 4b/Ebstein Bar	GBV-C/Hepatitis G Virus
Bad Nutritional Factors - Low Zinc, low alpha lipoate,low antioxidants	Good Nutritional Factors - Zinc, alpha lipoate,antioxidants
Muscle Waisting, Obesity	Muscle Building Exercise
Rapidly progressing or Drug resistant Viral genotypes	Slowly or nonprogressing Viral genotypes
High NGF levels	Low NGF levels
Use of amphetamines	3 or more Anti-viral drug therapy
Psycho-Social Factors (stress, finances, lack of support, non-compliance with medication regimen)	Psycho-Social Factors (low stress, good finances, good support, compliance with medication regimen)
Host Genotypes CCR5 variants,CXCR4 variants, homozygosity of HLA class I alleles, HLA -A 24,HLA-B 18,39,35Px, w6 variants, APOBEC3G low activity or Vif-high binding variants and CUL5-elongins B, C, + Rbx1 functional complexes, human topoisomerase high activity variants, hp32 splicing factor variants, human RNA Helicase A variants. TRIM5-alpha low activity variants	Host Genotypes CCR5 delta32, CCR5 promotor variants, CCR2-v64I, CXCR4 variants,HLA -A 1101 , HLA-B 27, 44, 55, 57-01/03, w4, HLA-DR5, rare HLA supertypes, APOBEC3G high activity or Vif-low binding variants and/or CUL5-elongins B, C, + Rbx1 nonfunctional complexes, human topoisomerase low activity variants, hp32 splicing factor variants, human RNA Helicase A variants. TRIM5-alpha high activity variants